Product Name: Biotin-CCL5 (Rantes)

Catalog Numbers: B-CCL5-2ug B-CCL5-10ug B-CCL5-50ug B-CCL5-100ug

DESCRIPTION

Source	E. coli derived Accession # P13501 (24-91)
Modification	Biotinylated
Predicted Molecular Mass	10,269.7258 Da
Extinction Coefficient	18,020 M-1 cm-1

SPECIFICATIONS

Activity	EC50 = 0.25-0.50nM determined by Migration Assay of recombinant CCR5 containing cells
Actual Molecular Mass (Mass Spec)	10,269.7258 Da by ESI Mass Spec
Endotoxin Level	<0.01 EU per 1µg of the protein by the LAL method
Purity	> 97% by SDS PAGE
Formulations	Lyophilized
Carrier Protien	None

PREPARATION AND STORAGE

Reconsitituion	Spin tube prior to resuspending. Recommended at 100µg/mL in sterile water
Shipping	Room Temp

Stability and Storage

Avoid repeated freeze-thaw cycles

- 12 months from date of receipt, -20 to -70 °C as supplied.
- Suggest to use immediately after reconstitution
- At least 1 month at -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Description

Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) (CCL5) is a proinflammatory chemokine that induces migration and activation of leukocytes, as well as implication in HIV infection. It binds to cell surface receptors CCR1, CCR3, CCR4, and CCR5. Its biological effects on leukocyte activation and HIV infection displays dependence on concentration and on the binding of cell surface glycosaminoglycans.

References:

1. “RANTES: a versatile and controversial chemokine”
Appay V., Rowland-Jones S.L.
Trends Immunol 22:83-87 (2001)

2. “Identification of RANTES, MIP-1, and MIP-1[1] as the major HIV-suppressive factors produced by CD8+T cells”
Cocchi F., De Vico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P.
Science 270:1811-1815 (1995)

3. A human T cell-specific molecule is a member of a new gene family
Schall T.J., Jongstra J., Dyer B.J., Jorgensen J., Clayberger C., Davis M.M., Krensky A.M.
J Immunol 141:1018-1025 (1988)

4. “Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists”
Brandner B., Rek A., Diedrichs-Möhring M., Wildner G., Kungl A.J.
Protein Eng Des Sel. 22:367-373 (2009)